« Return to News | Awards & Advancement

Moderna Therapeutics names Joseph Bolen president of R&D

Thursday, August 1, 2013 12:27 PM

Moderna Therapeutics, developing messenger RNA therapeutics, a new treatment modality to enable the in vivo production of therapeutic proteins, has hired Joseph Bolen, Ph.D., as its president of R&D.

Bolen will oversee all aspects of R&D at Moderna, including discovery research, preclinical and clinical development and clinical operations. His team will drive the discovery and development of compounds to support Moderna's existing and future research partnerships, as well as its internal efforts in rare diseases and oncology.

Bolen, the former chief scientific officer and global head of oncology research at Millennium: The Takeda Oncology Company, has held senior leadership positions at Millennium since 1999. Previously, Bolen held senior R&D positions at Hoechst Marion Roussel, Schering-Plough and Bristol-Myers Squibb. He has more than 30 years of industry and research experience and has been at the forefront of cancer and immunology research since starting his career as a scientist at the NIH, where he spent 10 years making contributions to the discovery of a class of proteins known as tyrosine kinase oncogenes as key regulators of the immune system.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.